Skip to main content

Table 6 Fisher’s exact test for AFF in univariate analysis

From: Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review

  Category Incidence rate (95% CI) p-value
All   0.018 (0.006–0.042)  
Primary disease Breast 0.025 (0.007–0.064) 0.3968
Other 0.008 (0–0.046)  
Stage at diagnosis Stage 1–2 0.013 (0–0.069) 1
Stage 3–4 0.014 (0.002–0.051)  
Gender Female 0.027 (0.009–0.063) 0.1713
Male 0 (0–0.039)  
Age < 65 0.023 (0.005–0.065) 0.6716
> = 65 0.014 (0.002–0.049)  
Metastatic site: liver No 0.03 (0.01–0.068) 0.1601
Yes 0 (0–0.034)  
Metastatic site: lung No 0.013 (0.002–0.045) 0.6548
Yes 0.025 (0.005–0.072)  
Metastatic site: lymph node No 0.023 (0.005–0.066) 0.669
Yes 0.014 (0.002–0.049)  
Metastatic site: femur No 0.021 (0.007–0.049) 1
Yes 0 (0–0.086)  
Number of denosumab doses < 10 0 (0–0.027) 0.0605
> = 10 0.035 (0.012–0.081)  
Number of denosumab doses < 25 0.005 (0–0.025) 0.0057
> = 25 0.074 (0.021–0.179)  
Prior zoledronic acid treatment No 0.006 (0–0.033) 0.0151
Yes 0.071 (0.02–0.173)  
\